These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 35102712)

  • 1. A modeling-based proposal for safe and efficacious reintroduction of bedaquiline after dose interruption: A population pharmacokinetics study.
    Keutzer L; Akhondipour Salehabad Y; Davies Forsman L; Simonsson USH
    CPT Pharmacometrics Syst Pharmacol; 2022 May; 11(5):628-639. PubMed ID: 35102712
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimized Loading Dose Strategies for Bedaquiline When Restarting Interrupted Drug-Resistant Tuberculosis Treatment.
    Koele SE; van Beek SW; Maartens G; Brust JCM; Svensson EM
    Antimicrob Agents Chemother; 2022 Mar; 66(3):e0174921. PubMed ID: 35007141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Addressing bedaquiline treatment interruptions in the treatment of drug-resistant TB.
    Kambili C; Rossenu S; Hoetelmans RMW; Birmingham E; Bakare N
    Int J Tuberc Lung Dis; 2022 Jul; 26(7):671-677. PubMed ID: 35768912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exposure-safety analysis of QTc interval and transaminase levels following bedaquiline administration in patients with drug-resistant tuberculosis.
    Tanneau L; Svensson EM; Rossenu S; Karlsson MO
    CPT Pharmacometrics Syst Pharmacol; 2021 Dec; 10(12):1538-1549. PubMed ID: 34626526
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term plasma pharmacokinetics of bedaquiline for multidrug- and extensively drug-resistant tuberculosis.
    Perrineau S; Lachâtre M; Lê MP; Rioux C; Loubet P; Fréchet-Jachym M; Gonzales MC; Grall N; Bouvet E; Veziris N; Yazdanpanah Y; Peytavin G
    Int J Tuberc Lung Dis; 2019 Jan; 23(1):99-104. PubMed ID: 30674381
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predicting the Outcomes of New Short-Course Regimens for Multidrug-Resistant Tuberculosis Using Intrahost and Pharmacokinetic-Pharmacodynamic Modeling.
    Doan TN; Cao P; Emeto TI; McCaw JM; McBryde ES
    Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30249697
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of the side effect of QTc interval prolongation in the bedaquiline regimen in drug resistant tuberculosis patients.
    Ardhianto D; Suharjono ; Soedarsono ; Fatmawati U
    J Basic Clin Physiol Pharmacol; 2021 Jun; 32(4):421-427. PubMed ID: 34214323
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development and Validation of a Nomogram for Prediction of QT Interval Prolongation in Patients Administered Bedaquiline-Containing Regimens in China: a Modeling Study.
    Liu F; Gao J; Gao M; Liu Y; Shu W; Xie L; Sun Y; Zhang L; Li L; Pang Y
    Antimicrob Agents Chemother; 2022 Sep; 66(9):e0203321. PubMed ID: 36047781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bedaquiline Effect on QT Interval of Drugs-Resistant Tuberculosis Patients: Real World Data.
    Darmayani IGAAPS; Ascobat P; Instiaty I; Sugiri YJR; Sawitri N
    Acta Med Indones; 2022 Jul; 54(3):389-396. PubMed ID: 36156479
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early treatment outcome of bedaquiline plus optimised background regimen in drug resistant tuberculosis patients.
    Barvaliya SV; Desai MK; Panchal JR; Solanki RN
    Indian J Tuberc; 2020 Apr; 67(2):222-230. PubMed ID: 32553316
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic interaction between bedaquiline and clofazimine in patients with drug-resistant tuberculosis.
    Maartens G; Brill MJE; Pandie M; Svensson EM
    Int J Tuberc Lung Dis; 2018 Jan; 22(1):26-29. PubMed ID: 29145924
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness and safety of bedaquiline under conditional access program for treatment of drug-resistant tuberculosis in India: An interim analysis.
    Salhotra VS; Sachdeva KS; Kshirsagar N; Parmar M; Ramachandran R; Padmapriyadarsini C; Patel Y; Mehandru L; Jaju J; Ponnuraja C; Gupta M; Kalaiselvan V; Shamim A; Khaparde S; Swaminathan S;
    Indian J Tuberc; 2020 Jan; 67(1):29-37. PubMed ID: 32192613
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dose- and Time-dependency of the Toxicity and Pharmacokinetic Profiles of Bedaquiline and Its N-desmethyl Metabolite in Dogs.
    Smyej I; De Jonghe S; Looszova A; Mannens G; Verhaeghe T; Thijssen S; Starckx S; Lampo A; Rouan MC
    Toxicol Pathol; 2017 Jul; 45(5):663-675. PubMed ID: 28789609
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness and safety of bedaquiline-containing regimens for treatment on patients with refractory RR/MDR/XDR-tuberculosis: a retrospective cohort study in East China.
    Zhang SJ; Yang Y; Sun WW; Zhang ZS; Xiao HP; Li YP; Zhang ZM; Fan L
    BMC Infect Dis; 2022 Aug; 22(1):715. PubMed ID: 36038829
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis in China.
    Han X; Chen X; Sha W; Zhang X; Qiu L; Wang J; Wu G; Yao L; Lv Y; Zhang X; Zhou J; Tang S; Chu N
    Int J Tuberc Lung Dis; 2020 Aug; 24(8):789-794. PubMed ID: 32912383
    [No Abstract]   [Full Text] [Related]  

  • 16. Modeling the impact of bedaquiline treatment strategies on the multidrug-resistant tuberculosis burden in India.
    Mehra M; Kambili C; Potluri R; Rhines A; Singh V; Thomas A
    Int J Tuberc Lung Dis; 2017 Aug; 21(8):902-909. PubMed ID: 28786799
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bedaquiline for multidrug-resistant TB in paediatric patients.
    Moodliar R; Aksenova V; Frias MVG; van de Logt J; Rossenu S; Birmingham E; Zhuo S; Mao G; Lounis N; Kambili C; Bakare N
    Int J Tuberc Lung Dis; 2021 Sep; 25(9):716-724. PubMed ID: 34802493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative Efficacy of the Novel Diarylquinoline TBAJ-876 and Bedaquiline against a Resistant
    Almeida D; Converse PJ; Li SY; Upton AM; Fotouhi N; Nuermberger EL
    Antimicrob Agents Chemother; 2021 Nov; 65(12):e0141221. PubMed ID: 34570644
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acquisition of clofazimine resistance following bedaquiline treatment for multidrug-resistant tuberculosis.
    Liu Y; Gao J; Du J; Shu W; Wang L; Wang Y; Xue Z; Li L; Xu S; Pang Y
    Int J Infect Dis; 2021 Jan; 102():392-396. PubMed ID: 33130209
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emergence of nontuberculous mycobacteria infections during bedaquiline-containing regimens in multidrug-resistant tuberculosis patients.
    Gao J; Pei Y; Yan X; Shi G; Li T; Gao M; Liu Y; Wang Y; Shu W; Li L; Pang Y
    Int J Infect Dis; 2020 Nov; 100():196-198. PubMed ID: 32890726
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.